Market Research Logo

3D Cell Culture

3D Cell Culture

SMi Group proudly presents the inaugural launch of 3D Cell Culture, an exciting new conference scheduled to take place on the 22nd and 23rd February 2017, London UK. Following the success of our Advances in Cell Based Assays series, 3D Cell Culture is set to become a leading event for industry. 3D Cell Culture 2017 will address the latest developments of 3D cell culture techniques; the ways in which predictive 3D models are presently paving the way to future technologies, and the ways in which they are currently revolutionizing drug discovery and screening and disease modelling. The 3D cell culture market is predicted to reach $3702.2 million by 2021* with main increase seen in novel technologies and culture methods. This event will highlight emerging technologies, like 3D and 4D bio imaging, and their application in furthering research and medical practice. In addition, there will be focus on organoid technology and the involvement of 3D culture methods in drug and toxicology screening, topics of great current commercial interest to pharmaceutical and research bodies.

3D Cell Culture 2017 will bring together leading professionals and researchers in the industry to discuss the latest developments and future potential of this technique. 3D Cell Culture 2017 will present success stories 3D culture applications, identifying the newest and brightest technologies, and the translation of 3D models into successful clinical and industrial applications. There will be emphasis on the success and future of 3D methods in organoid research, disease modeling and toxicology screening, stem cell research, and much more.

We look forward to meeting you in February!


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks : An introduction to 3D methods; Challenges, changes, and the relationships between science and technology
Stefan Przyborski, Founder and CSO, Durham University
9:10
An introduction to 3D methods; Challenges, changes, and the relationships between science and technology
Stefan Przyborski, Founder and CSO, Durham University
9:50
Bridging the gap between 2D and in vivo: tumour spheroid-based assays for target validation and screening
Radek Polanski, Senior Research Scientist , AstraZeneca
10:30
Morning Coffee
10:50
Emerging technologies in 3D cell culture for drug discovery
Oliver Chao, Head, Emerging Biomedical Sciences, sanofi-aventis
11:30
Using 3D spheroids and microtissue methods to investigate hepatotoxicity
Carlo Cusulin , Postdoctoral Researcher , Roche Diagnostics
12:10
Networking Lunch
13:30
HipSci and the ‘Stem cell hotel’, an innovative platforms for collaborative phenotyping
Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
14:10
CRISPR engineered organoids for modelling genetic and infectious brain disease
Max Salick, Postdoctoral Researcher, Novartis Institutes For Biomedical Research
14:50
Afternoon Tea
15:10
Human in vitro 3D lung models for efficacy and toxicity assessment
Samuel Constant, COO, Epithelix
15:50
Using 3D spheroids and microtissue methods to investigate hepatotoxicity
Christopher Schofield, Investigator, GSK
16:30
Chairman’s Closing Remarks and Close of Day One
Stefan Przyborski, Founder and CSO, Durham University
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Robert Vries, Managing Director, Hubrecht Institute
9:10
EU Regulatory considerations for the use of cells in drug manufacturing (quality focus)
Louise Bisset, Biopharmaceutical Quality Assessor, MHRA
9:50
3D organoid cultures: a personalised model for drug discovery as well as companion diagnostics
Robert Vries, Managing Director, Hubrecht Institute
10:30
Morning Coffee
10:50
Screening of Mouse Intestinal Crypt Cultures: A simple readout for complex biology
Olaf Galuba, Scientist, Novartis Pharmaceuticals
11:30
Multi-Organ on a chip technologies; potential impact on predictive substance testing
Reyk Horland, Head of Business Development, Tissuse G Mb H
12:10
Networking Lunch
13:30
Organ printing and the potential of guided angiogenesis
William Whitford, Strategic Solutions Leader, GE Healthcare
14:10
Leaving 2D behind – considerations and approaches to translating cell therapy manufacturing into 3D
Eytan Abraham, Head of Research & Technology for Emerging Technologies, Lonza Incorporated
14:50
Afternoon Tea
15:10
Automatic mechano-profiling of cells – A new angle on cancer cell assays
Nils Goedecke, Founder, Microduits GmbH
15:50
Fast 3D imaging in multiwell plates
Christopher Dunsby, Senior Lecturer, Imperial College
16:30
Chairman’s Closing Remarks and Close of Day Two
Robert Vries, Managing Director, Hubrecht Institute

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report